Replimune Group, Inc. (REPL) Research

Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.

Market snapshot

Symbol
REPL
Price
$10.19
Day change
+1.90%
Market cap
$841.4M
P/E ratio
-2.98x
52-week range
1.5-13.24
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 1 month
Analyst price target
$14.00

Recent news

  • How Replimune's drug got a third chance after the White House intervened

    Replimune representatives met with White House officials in early May and by the end of month, the Food and Drug Administration was planning to review the melanoma medication again.

  • Replimune to resubmit twice-rejected drug for approval after FDA shakeup

    Replimune said it plans to resubmit its melanoma drug for approval following two earlier rejections. The move follows the departure of Food and Drug Administration Commissioner Marty Makary.

  • Replimune reaches agreement with US FDA to resubmit melanoma drug application

    Replimune said ​on Friday ‌it it has reached ​an ​agreement with the ⁠U.S. ​Food and ​Drug Administration to resubmit the ​marketing ​application for its ‌experimental ⁠skin cancer drug after ​the ​regulator ⁠twice declined to ​approve ​the ⁠therapy.

Peer companies

  • Arvinas, Inc. (ARVN)
  • Astria Therapeutics, Inc. (ATXS)
  • ArriVent BioPharma, Inc. Common Stock (AVBP)
  • Ginkgo Bioworks Holdings, Inc. (DNA)
  • Iovance Biotherapeutics, Inc. (IOVA)
  • MBX Biosciences, Inc. Common Stock (MBX)
  • MeiraGTx Holdings plc (MGTX)
  • Prime Medicine, Inc. (PRME)

Recent insider activity

  • Sarchi Christopher — S-Sale (12000 shares) on 2026-06-01
  • Xynos Konstantinos — S-Sale (14023 shares) on 2026-05-18
  • Schwendenman Andrew — S-Sale (7894 shares) on 2026-05-18
  • Sarchi Christopher — S-Sale (8626 shares) on 2026-05-18
  • Astley-Sparke Philip — S-Sale (17657 shares) on 2026-05-18

Open Replimune Group, Inc. (REPL) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.